[go: up one dir, main page]

MX2018004600A - Celulas aniquiladoras naturales y células ilc3 y usos de las mismas. - Google Patents

Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.

Info

Publication number
MX2018004600A
MX2018004600A MX2018004600A MX2018004600A MX2018004600A MX 2018004600 A MX2018004600 A MX 2018004600A MX 2018004600 A MX2018004600 A MX 2018004600A MX 2018004600 A MX2018004600 A MX 2018004600A MX 2018004600 A MX2018004600 A MX 2018004600A
Authority
MX
Mexico
Prior art keywords
cells
natural
ilc3
methods
killer
Prior art date
Application number
MX2018004600A
Other languages
English (en)
Inventor
J Hariri Robert
Zhang Xiaokui
Edinger James
Kang Lin
Law Eric
Hofgartner Wolfgang
Stout Bhavani
Voskinarian-Berse Vanessa
Djuretic Ivana
Jankovic Vladimir
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity Inc filed Critical Celularity Inc
Publication of MX2018004600A publication Critical patent/MX2018004600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

En la presente se proporcionan métodos de producción de células aniquiladoras naturales (NK) y/o células ILC3 mediante el uso de un método de expansión y diferenciación en tres etapas con un medio que comprende factores de movilización de células madre. También en la presente se proporcionan métodos para suprimir la proliferación de las células tumorales mediante el uso las células aniquiladoras naturales NK y/o las células ILC3 y las poblaciones de células aniquiladoras naturales NK y/o células ILC3 que se producen por medio de los métodos en tres etapas descritos en la presente, así como para el tratamiento de individuos que tengan cáncer o una infección viral, los cuales comprenden administrar las células aniquiladoras naturales NK y/o células ILC3 y las poblaciones de células aniquiladoras naturales NK y/o células ILC3 que se producen por medio de los métodos en tres etapas descritos en la presente a un individuo que tenga cáncer o la infección viral.
MX2018004600A 2015-10-15 2016-10-14 Celulas aniquiladoras naturales y células ilc3 y usos de las mismas. MX2018004600A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562242246P 2015-10-15 2015-10-15
US201562272984P 2015-12-30 2015-12-30
US201662403571P 2016-10-03 2016-10-03
PCT/US2016/056988 WO2017066530A1 (en) 2015-10-15 2016-10-14 Natural killer cells and ilc3 cells and uses thereof

Publications (1)

Publication Number Publication Date
MX2018004600A true MX2018004600A (es) 2019-09-04

Family

ID=58517926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004600A MX2018004600A (es) 2015-10-15 2016-10-14 Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.

Country Status (17)

Country Link
US (2) US20180346877A1 (es)
EP (1) EP3362075B1 (es)
JP (3) JP2018535666A (es)
KR (1) KR20180059555A (es)
CN (1) CN109310710A (es)
AU (1) AU2016340005B2 (es)
BR (1) BR112018007538A2 (es)
CA (1) CA3002066A1 (es)
CO (1) CO2018004937A2 (es)
EA (1) EA201890960A1 (es)
IL (1) IL258666B2 (es)
MX (1) MX2018004600A (es)
MY (1) MY201637A (es)
NZ (1) NZ741612A (es)
SG (2) SG10201912576PA (es)
TW (1) TW201732037A (es)
WO (1) WO2017066530A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2019067792A1 (en) * 2017-09-28 2019-04-04 Celularity, Inc. TUMOR CONTROL WITH INTERMEDIATE NATURAL KILLER CELLS DERIVED FROM HUMAN PLACENTA (PINK) IN COMBINATION WITH ANTIBODY
EP3755355A4 (en) * 2018-02-20 2022-01-05 Universite De Montreal Expansion of nk and dc cells in vivo mediating immune response
CN108486054B (zh) * 2018-04-12 2022-04-19 平安爱普德（北京）生物技术有限公司 一种体外扩增i型天然细胞毒性淋巴细胞ilc1/nk的方法
CN113454207A (zh) * 2018-11-30 2021-09-28 细胞结构公司 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞
WO2020231200A1 (ko) * 2019-05-15 2020-11-19 오정훈 효율적 자연살해세포 배양방법 및 이의 배지첨가 키트
WO2020252464A1 (en) * 2019-06-14 2020-12-17 Celularity Inc. Populations of natural killer cells for treating cancers
JP2022542321A (ja) * 2019-07-29 2022-09-30 デヴェラ セラピューティクス インコーポレイテッド 免疫療法のためのｎｋ細胞組成物および調製物ならびにそれらの製造のための方法
WO2021119834A1 (en) * 2019-12-18 2021-06-24 Universite De Montreal Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds
WO2021155312A1 (en) * 2020-01-29 2021-08-05 Celularity Inc. Placental derived natural killer cells for treatment of coronavirus infections
US12195759B2 (en) * 2020-02-21 2025-01-14 FullHope Biomedical Co., Ltd. Modified natural killer cells, pharmaceutical composition, manufacturing method thereof, and method of using the same
JP2021136883A (ja) * 2020-03-02 2021-09-16 株式会社ガイアバイオメディシン 高活性ｎｋ細胞の処理方法
KR20220048775A (ko) * 2020-10-13 2022-04-20 주식회사 노보셀바이오 Nk 세포를 유효성분으로 포함하는 항바이러스 조성물
CN112285083B (zh) * 2020-10-28 2022-01-07 上海睿钰生物科技有限公司 一种细胞杀伤效力的评价方法
CN112251406B (zh) * 2020-10-30 2023-06-09 曹峰林 一种nk细胞活化阶段的外泌体分选方法
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
US11473060B2 (en) 2020-12-30 2022-10-18 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into NK cells
KR20240063899A (ko) * 2021-09-08 2024-05-10 가부시키가이샤 가이아바이오메디신 세포의 처리 방법
WO2025028596A1 (ja) * 2023-08-02 2025-02-06 株式会社ヘリオス ナチュラルキラー細胞の製造方法
CN117511867B (zh) * 2023-10-07 2024-08-06 深圳泽医细胞治疗集团有限公司 一种靶向肺部且高表达nkg2d的nk细胞的培养试剂盒及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US9862928B2 (en) * 2010-12-03 2018-01-09 Regents Of The University Of Minnesota Generation of natural killer cells and lymphoid tissue inducer-like (LTi-like) NK-22 cells
PL2686421T3 (pl) * 2011-03-18 2021-05-31 Glycostem Therapeutics B.V. Generowanie komórek nk i progenitorów komórek nk
PL2807165T3 (pl) * 2012-01-27 2019-09-30 Université de Montréal Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
WO2013119118A1 (en) 2012-02-08 2013-08-15 Ipd-Therapeutics B.V. Ex vivo nk cell differentiation from cd34+ hematopoietic cells
AU2013302853A1 (en) * 2012-08-13 2015-03-05 Anthrogenesis Corporation Natural killer cells and uses thereof
US9074186B2 (en) * 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
WO2015035063A2 (en) * 2013-09-05 2015-03-12 Sanford-Burnham Medical Research Institute MODULATION OF γδT CELLS
JP6417413B2 (ja) * 2013-10-17 2018-11-07 ナショナル ユニヴァーシティー オブ シンガポール 多様な腫瘍に対する抗体依存性細胞毒性を誘発するキメラ受容体
EP3240552A4 (en) * 2014-12-31 2018-06-20 Anthrogenesis Corporation Natural killer cells and uses thereof
WO2017046142A1 (en) * 2015-09-15 2017-03-23 Stichting Katholieke Universiteit IMPROVED METHOD FOR EX VIVO EXPANSION CD34+HSPCs INTO NK CELLS USING AN ARYL HYDROCARBON RECEPTOR ANTAGONIST
SG11201809858RA (en) * 2016-05-07 2018-12-28 Celularity Inc Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

Also Published As

Publication number Publication date
JP2023171766A (ja) 2023-12-05
JP2018535666A (ja) 2018-12-06
KR20180059555A (ko) 2018-06-04
MY201637A (en) 2024-03-06
US20230142803A1 (en) 2023-05-11
AU2016340005B2 (en) 2023-09-07
CA3002066A1 (en) 2017-04-20
EP3362075A4 (en) 2019-04-17
IL258666B1 (en) 2024-05-01
IL258666A (en) 2018-06-28
WO2017066530A1 (en) 2017-04-20
NZ741612A (en) 2022-12-23
SG11201803117YA (en) 2018-05-30
EP3362075A1 (en) 2018-08-22
EA201890960A1 (ru) 2018-10-31
CN109310710A (zh) 2019-02-05
IL258666B2 (en) 2024-09-01
AU2016340005A1 (en) 2018-05-10
TW201732037A (zh) 2017-09-16
EP3362075B1 (en) 2023-06-07
BR112018007538A2 (pt) 2018-10-23
CO2018004937A2 (es) 2018-09-28
US20180346877A1 (en) 2018-12-06
JP2022023148A (ja) 2022-02-07
SG10201912576PA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
BR112017014269A2 (pt) células exterminadoras naturais e usos das mesmas
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
CL2025001440A1 (es) Medios y método para preparar vectores virales y usos de los mismos
MX342995B (es) Métodos de generar células asesinas naturales.
CL2017002728A1 (es) Método para el tratamiento de cáncer
CO2019011450A2 (es) Expresión transgénica selectiva de tejidos
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2021006398A (es) Expansión de células asesinas naturales y células ilc3 con compuestos aromáticos novedosos.
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
MX2018013864A (es) Métodos para la expansión selectiva de poblaciones de células t gama y composicicones de estas.
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
BR112021008738A2 (pt) Processo para produzir células t geneticamente construídas
MX2017017079A (es) Sistema de administracion dirigida de principio activo celular.
AR094375A1 (es) Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular
CL2018003421A1 (es) Combinaciones farmacéuticas.
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
MX2017006685A (es) Tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas usando terapias reductoras de amoniaco.
MX2018006373A (es) Produccion de virus en cultivos celulares.
BR112021013971A2 (pt) Composições e métodos para estimular células natural killer
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
CO2018001615A2 (es) Fosforamidocloridato morfolino nucleósidos activados diastereoméricamente puros o sustancialmente diastereoméricamente puros y métodos para su preparación
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
MX2018003757A (es) Composiciones y metodos para producir celulas dendriticas.